- Home
- NNE vs MREO Comparison
NNE vs MREO Comparison
Compare NNE & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NNE
- MREO
- Stock Information
- Founded
- NNE 2022
- MREO 2015
- Country
- NNE United States
- MREO United Kingdom
- Employees
- NNE N/A
- MREO N/A
- Industry
- NNE
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- NNE
- MREO Health Care
- Exchange
- NNE NYSE
- MREO Nasdaq
- Market Cap
- NNE 718.5M
- MREO 577.6M
- IPO Year
- NNE 2024
- MREO N/A
- Fundamental
- Price
- NNE $19.56
- MREO $4.21
- Analyst Decision
- NNE Strong Buy
- MREO Strong Buy
- Analyst Count
- NNE 2
- MREO 4
- Target Price
- NNE $44.50
- MREO $7.50
- AVG Volume (30 Days)
- NNE 6.1M
- MREO 531.9K
- Earning Date
- NNE 11-14-2024
- MREO 11-13-2024
- Dividend Yield
- NNE N/A
- MREO N/A
- EPS Growth
- NNE N/A
- MREO N/A
- EPS
- NNE N/A
- MREO N/A
- Revenue
- NNE N/A
- MREO $1,000,000.00
- Revenue This Year
- NNE N/A
- MREO $16.39
- Revenue Next Year
- NNE N/A
- MREO $9.44
- P/E Ratio
- NNE N/A
- MREO N/A
- Revenue Growth
- NNE N/A
- MREO N/A
- 52 Week Low
- NNE $3.25
- MREO $1.86
- 52 Week High
- NNE $37.51
- MREO $5.02
- Technical
- Relative Strength Index (RSI)
- NNE N/A
- MREO 45.46
- Support Level
- NNE N/A
- MREO $4.13
- Resistance Level
- NNE N/A
- MREO $4.31
- Average True Range (ATR)
- NNE 0.00
- MREO 0.20
- MACD
- NNE 0.00
- MREO -0.03
- Stochastic Oscillator
- NNE 0.00
- MREO 23.88
About NNE NANO NUCLEAR ENERGY INC
Nano Nuclear Energy Inc is an early-stage nuclear energy company developing smaller, cheaper, and safer advanced portable clean energy solutions. It is focused on four business lines as part of development: Micro Nuclear Reactor Business is developing the next-generation nuclear microreactors, in particular ZEUS, a solid core battery reactor, and ODIN, a low-pressure salt coolant reactor. Fuel Fabrication Business, Fuel Transportation Business and Nuclear Consultation Services.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).